ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC). Grivas, P., Vogelzang, N. J., Alva, A., Feyerabend, S., Loriot, Y., Necchi, A., Gupta, S., Josephs, D., Rodriguez-Vida, A., Srinivas, S., Zakharia, Y., Wride, K., Thomas, D., Dusek, R., Simmons, A., Nepert, D. L., Chowdhury, S. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.7_suppl.TPS496

View details for Web of Science ID 000489108800029